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anovulatory polycystic ovary syndrome phenotype
Abstract
BACKGROUND: Dyslipidemia is common in women with polycystic ovary syndrome (PCOS) but its
prevalence in different PCOS phenotypes is still largely unknown. METHODS: We measured plasma
lipids and lipoproteins in 35 anovulatory PCOS (age: 25 +/- 6 years, BMI: 28 +/- 6 kg/m(2)), 15
ovulatory PCOS (age: 30 +/- 6 years, BMI: 25 +/- 3 kg/m(2)) and 27 healthy women (controls) age- and
BMI-matched with ovulatory PCOS. PCOS was diagnosed by the presence of clinical or biologic
hyperandrogenism associated with chronic anovulation and/or polycystic ovaries at ultrasound. In
women with normal menses chronic anovulation was indicated by low serum progesterone levels (<9.54
nmol/l) during midluteal phase (days 21-24) in two consecutive menstrual cycles. RESULTS: Total
cholesterol, triglycerides and low-density lipoprotein (LDL)-cholesterol levels increased and
high-density lipoprotein (HDL)-cholesterol decreased from controls to ovulatory and then to
anovulatory PCOS (all P < 0.05). Levels of lipoprotein(a) (Lp(a)) and small, dense LDL increased (P <
0.0001 for both) and LDL size reduced (P < 0.005) between groups. Insulin resistance (by HOMA)
showed a positive correlation with triglycerides and small, dense LDL and an inverse correlation with
HDL-cholesterol and LDL size (P < 0.05 for all) in both PCOS phenotypes. No significant correlations
were found with testosterone levels. At multivariate analysis, insulin resistance was independently
associated with HDL-cholesterol and small, dense LDL in both PCOS phenotypes and with triglyceride
concentrations in ovulatory PCOS only. CONCLUSIONS: Women with ovulatory PCOS showed milder
forms of atherogenic dyslipidemia than anovulatory PCOS and this seemed to be related to the extent of
insulin resistance. Future prospective studies are needed to assess the relative contribution of such
alterations on cardiovascular risk.
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background: Dyslipidemia is common in women with polycystic ovary syndrome (PCOS) but its prevalence in different PCOS
phenotypes is still largely unknown.
methods: We measured plasma lipids and lipoproteins in 35 anovulatory PCOS (age: 25+ 6 years, BMI: 28+6 kg/m2), 15 ovulatory
PCOS (age: 30+6 years, BMI: 25+3 kg/m2) and 27 healthy women (controls) age- and BMI-matched with ovulatory PCOS. PCOS was
diagnosed by the presence of clinical or biologic hyperandrogenism associated with chronic anovulation and/or polycystic ovaries at
ultrasound. In women with normal menses chronic anovulation was indicated by low serum progesterone levels (,9.54 nmol/l) during
midluteal phase (days 21–24) in two consecutive menstrual cycles.
results: Total cholesterol, triglycerides and low-density lipoprotein (LDL)-cholesterol levels increased and high-density lipoprotein
(HDL)-cholesterol decreased from controls to ovulatory and then to anovulatory PCOS (all P, 0.05). Levels of lipoprotein(a) (Lp(a))
and small, dense LDL increased (P, 0.0001 for both) and LDL size reduced (P, 0.005) between groups. Insulin resistance (by HOMA)
showed a positive correlation with triglycerides and small, dense LDL and an inverse correlation with HDL-cholesterol and LDL size
(P, 0.05 for all) in both PCOS phenotypes. No signiﬁcant correlations were found with testosterone levels. At multivariate analysis,
insulin resistance was independently associated with HDL-cholesterol and small, dense LDL in both PCOS phenotypes and with triglyceride
concentrations in ovulatory PCOS only.
conclusions: Women with ovulatory PCOS showed milder forms of atherogenic dyslipidemia than anovulatory PCOS and this
seemed to be related to the extent of insulin resistance. Future prospective studies are needed to assess the relative contribution of
such alterations on cardiovascular risk.
Key words: polycystic ovary syndrome / lipids / lipoproteins / cardiovascular risk
Introduction
Polycystic ovary syndrome (PCOS) probably constitutes the most fre-
quently encountered endocrinopathy in women, affecting up to 10% of
women of reproductive age (Carmina and Lobo, 1999; Lobo and
Carmina, 2000). Although PCOS is known to be associated with
reproductive morbidity and increased risk for endometrial cancer,
diagnosis is especially important because the presence of PCOS
signiﬁcantly increases the cardiovascular risk, a ﬁnding which has
been consistently reported across several geographic areas and
ethnic groups (Rizzo et al., 2009). Women with PCOS are more
likely than normally cycling women to have insulin resistance, central
adiposity and hypertension (Guzick, 2004). In addition, several
markers of clinical and subclinical atherosclerosis are altered in
women with PCOS (Talbott et al., 2000; Christian et al., 2003; Orio
et al., 2004; Carmina et al., 2006).
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Dyslipidemia may represent the most common metabolic
abnormality in PCOS, with a prevalence of up to 70% according to
the National Cholesterol Education Program criteria (Legro et al.,
2001). Dyslipidemia usually includes low high-density lipoprotein
(HDL)-cholesterol, elevated triglyceride concentrations and less
often increased low-density lipoproteins (LDL) and total cholesterol
levels (Cussons et al., 2006). Evidences is accumulating that, beyond
plasma lipids, different lipoprotein alterations signiﬁcantly increase
cardiovascular risk, including elevated lipoprotein(a) (Lp(a)) levels,
increased concentrations of small, dense LDL and increased LDL
particle number, that can be measured indirectly as apolipoprotein
B (apoB) levels (National Cholesterol Education Program, 2002).
However, available data are not fully consistent on the prevalence
of the different forms of atherogenic dyslipidemia in women with
PCOS, which may be related to genetic and environmental factors
as well as the heterogeneity of PCOS phenotypes.
New diagnostic criteria have enlarged the spectrum of PCOS
phenotypes, now including ovulatory hyperandrogenic and anovula-
tory normoandrogenic women (Rotterdam, 2004; Azziz et al.,
2006). Such subgroups usually show a milder form of the syndrome
and may differ from classic PCOS (i.e. anovulatory hyperandrogenic
patients) by their gonadotrophin and steroid hormone secretion
pattern, severity of insulin resistance as well as body weight and car-
diovascular risk (Carmina, 2006; Barber et al., 2007). Yet, the exact
prevalence of atherogenic forms of dyslipidemia in women with
ovulatory versus anovulatory PCOS is unknown thus limiting the utility
of information we have on their cardiovascular risk. Therefore, we
studied 50 Mediterranean women with both anovulatory and
ovulatory PCOS, as well as 27 healthy women as controls, in order to
assess the differences in plasma lipids and lipoproteins between groups.
Materials and Methods
Patients and control subjects
We have included in the present study 50 women of reproductive age
(age: 18–40 years) who were consecutively diagnosed with PCOS at
the Endocrine Unit of the Department of Internal Medicine and Emerging
Diseases (University of Palermo, Italy). They were all referred because
of androgen excess (hirsutism or increased circulating androgens)
and serum levels of testosterone, dehydroepiandrosterone sulfate,
17-hydroxyprogesterone, progesterone and pelvic sonography were eval-
uated at the moment of their referral to our Endocrine Unit. Serum andro-
gens and 17-hydroxyprogesterone were measured during follicular phase
(days 5–8) although serum progesterone was determined in day 21–24
of menstrual cycle. Patients with increased 17-hydroxyprogesterone
(.9.1 nmol/l) were excluded from the study. Biochemical hyperandro-
genism was deﬁned as serum testosterone .2.08 nmol/l and/or serum
dehydroepiandrosterone sulfate .7800 nmol/l. These values of hyperan-
drogenism have been previously calculated in our population with the
same assays (Carmina, 1998).
Anovulation was deﬁned as serum progesterone ,9.54 nmol/l. In
patients with normal menses, at least two consecutive menstrual cycles
were studied and ﬁnding of low levels of serum progesterone
(,9.54 nmol/l) during midluteal phase (days 21–24) in both cycles indi-
cated the presence of chronic anovulation (Fisher, 2004). Thus, the
study included both anovulatory (n ¼ 35) and ovulatory (n ¼ 15) PCOS.
In all patients transvaginal sonography was performed using a Hitachi
H21 instrument by an experienced sonographer (e.g.) on day 5 of
menstrual cycle. Ovarian sonographies had to report ovarian size (by
measurement of the main three ovarian diameters in both ovaries) and
presence, size and number of ovarian microcysts. Finding of increased
ovarian size and/or of at least 12 follicular cysts measuring 2–9 mm
were considered indicative of the presence of polycystic ovaries (Balen
et al., 2003). According to this deﬁnition, all studied patients had polycystic
ovaries. The diagnosis of PCOS was based on the presence of clinical or
biologic hyperandrogenism associated with chronic anovulation and/or
polycystic ovaries at ultrasound (Azziz et al., 2006).
The project design included a medical examination and biochemical
analyses. The adopted procedures were in agreement with the Helsinki
Declaration of 1975 (6th revision, 2008) and the study was approved by
the local Ethics Council. All subjects gave their informed consent to par-
ticipate in the study. At admission all subjects underwent a medical exam-
ination and also answered a questionnaire on personal and medical items,
including age, past medical history and use of medications. Exclusion cri-
teria included the presence of type-2 diabetes, renal or hepatic diseases
able to modify plasma lipids and lipoproteins, including levels of
triglyceride-rich lipoproteins and small, dense LDL, as well as the use of
hypolipidemic drugs. The control group consisted of 27 healthy women
with the same exclusion criteria described above, which were age- and
BMI-matched with the group of ovulatory PCOS. They were recruited
from family members of hospital co-workers. Controls were women
with regular menses, normal ovulatory menses (progesterone during
midluteal phase .22.3 nmol/l) (Carmina and Lobo, 2004) and normal
androgen and 17-hydroxyprogesterone levels.
Height and weight were recorded and BMI was calculated as kg/m2.
Waist circumference was measured according to the American Heart
Association/National Heart, Lung and Blood Institute guidelines (Grundy
et al., 2005). We located top of right iliac crest and we placed a measuring
tape in a horizontal plane around abdomen at level of iliac crest. Before
reading tape measure, we ensured that tape was snug, not compressing
the skin and parallel to the ﬂoor. Measurement was made at the end of
a normal expiration. Among the cardiovascular risk factors, hypertension
(systolic or diastolic blood pressure, respectively, 140 or 90 mmHg
or previous pharmacological therapy with antihypertensive drugs), dia-
betes (fasting glucose plasma concentrations higher than 7.0 mmol/l or
previous pharmacological therapy with antidiabetic drugs or insulin),
smoking habit and family history of cardiovascular diseases (in ﬁrst
degree male relatives younger than 55 years of age and in ﬁrst degree
female relatives younger than 65 years of age) (National Cholesterol
Education Program, 2002) were also considered.
Laboratory analyses
A blood sample was collected from each subject after 14 h overnight
fast in sodium-EDTA tubes. Plasma total cholesterol and triglycerides
were measured on a Roche Modular System using commercial reagents
(Roche Diagnostics, Rotkreuz, Switzerland) with a coefﬁcient of variation
of 2.3 and 2.4%, respectively. HDL-cholesterol, Lp(a) and apoB levels
were measured on a Roche Integra 800 analyzer using commercial
assays (Roche Diagnostics) with a coefﬁcient of variation of 4.1, 2.3 and
1.2%, respectively. LDL-cholesterol was calculated according to the
Friedewald formula (Friedewald et al., 1972). Insulin resistance was deter-
mined by the homeostasis model assessment (HOMA) using the formula:
[fasting serum insulin (mU/ml)  fasting plasma glucose (mmol/l)/22.5]
(Matthews et al., 1985). Serum hormone levels were quantiﬁed by
well-established methods which had been validated previously in our lab-
oratory. All steroids were measured by speciﬁc radioimmunoassays after
extraction using previously described methods (Carmina et al., 1992)
with intra-assay and inter-assay coefﬁcients of variation not exceeding
6 and 15%, respectively.
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LDL size and subclasses were assessed by non-denaturing polyacryl-
amide gradient gel electrophoresis of whole plasma in Switzerland in the
laboratory of K.B. at 10–148C in 2–16% polyacrylamide gradient gels.
Gels were subjected to electrophoresis for 24 h at 125 V in tris borate
buffer (pH 8.3) as described elsewhere (Krauss and Burke, 1982). Gels
were ﬁxed and stained for lipids in a solution containing oil red O in
60% ethanol at 558C. Gels were placed on a light source and photo-
graphed using a Luminescent Image Analyzer, LAS-3000 of Fujiﬁlm, detec-
tion using white transmitted light source. Migration distance for each
absorbance peak was determined and the molecular diameter corre-
sponding to each peak was calculated from a calibration curve generated
from the migration distance of size standards of known diameter, which
includes carboxylated latex beads (Duke Scientiﬁc, Palo Alto, CA, USA),
thyroglobulin and apoferritin (HMW Std, Pharmacia, Piscataway, NJ,
USA) having molecular diameter of 380, 170 and 122 A˚, respectively,
and lipoprotein calibrators of previously determined particle size. LDL sub-
class distribution as percent of total LDL was calculated as previously
described (Krauss and Burke, 1982). Total small, dense LDL particles
were considered those obtained by the sum of individual LDL-III þ
LDL-IV subclasses (e.g. LDL-IIIA þ LDL-IIIB þ LDL-IVA þ LDL-IVB).
In order to assess if plasma lipids or lipoproteinswere abnormal in women
with ovulatory and anovulatory PCOS, the following cut-offs were
considered (National Cholesterol Education Program, 2002; Grundy et al.,
2005): high triglycerides if .1.7 mmol/l, low HDL-cholesterol if
,1.29 mmol/l, high LDL-cholesterol if .4.1 mmol/l, elevated Lp(a)
if .30 mg/dl, elevated apoB if .100 mg/dl. Higher levels of small, dense
LDL were considered as those greater than mean þ2SD of the values
of controls, as previously described (Berneis et al., 2007).
Statistical analysis
Statistical analyses were performed using Statview 5.0 (SAS Institute,
USA). Since Lp(a) concentrations were not normally distributed, a log
transformation was necessary to obtain a normal distribution. Univariate
analyses were performed using the Mann–Whitney U non-parametric
test for the numeric variables whereas the differences in the prevalence
for the nominal variables were analyzed by the Fisher’s exact test.
ANOVA was performed to assess the differences in clinical and biochemi-
cal parameters between groups, after adjustment for age and BMI. Corre-
lation analyses were performed using the Spearman rank correlation
method. Multivariate analysis (by multiple regression) was performed in
order to determine the effects of clinical and laboratory parameters on
plasma lipids and lipoproteins in ovulatory and anovulatory PCOS. As
shown in Table V, we built different models of multivariate analysis for
ovulatory and anovulatory PCOS with the following dependent variables:
HDL-cholesterol, triglycerides, Lp(a), apoB and small, dense LDL. The
independent variables were represented in each model by age, BMI,
waist circumference, HOMA and testosterone.
Results
As shown in Table I, ovulatory PCOS had similar age and BMI than
controls, although anovulatory PCOS were younger and had a larger
waist circumference (P, 0.01 for both). A clear trend towards
higher testosterone and insulin concentrations and HOMA values
from controls to ovulatory and to anovulatory PCOS (P, 0.0001 for
all) was noted. No signiﬁcant differences were found between the
three groups with respect to hypertension, diabetes, smoking habits
and family history of cardiovascular diseases (data not shown).
Total-cholesterol, triglyceride and LDL-cholesterol concentrations
were higher and HDL-cholesterol levels were lower in controls versus
ovulatory versus anovulatory PCOS (all P, 0.05, see Table II).
Similarly, concentrations of Lp(a), as log-transformed, and small,
dense LDL were higher in anovulatory as compared with ovulatory
PCOS (P, 0.0001 for both) although no changes were found in
apoB levels. A clear trend towards alterations in LDL subclass distri-
bution was noted between groups too (see Fig. 1): larger particles
decreased and smaller, more dense LDL increased from controls to
ovulatory and to anovulatory PCOS. As depicted in Table III,
women with ovulatory PCOS displayed milder forms of atherogenic
dyslipidemias in relation to those with the anovulatory phenotype.
By correlation analysis we found that testosterone levels did not cor-
relate with any plasma lipid or lipoprotein parameter in either PCOS
phenotypes (Table IV); by contrast, HOMA indices correlated posi-
tively with triglyceride concentrations and small dense LDL and inver-
sely with HDL-cholesterol and LDL size in both PCOS phenotypes.
We also performed multivariate analysis (multiple regression) in
order to determine potential independent predictors of plasma
lipids and lipoproteins in ovulatory and anovulatory PCOS (see
Table V). We found that in both groups insulin resistance was indepen-
dently associated with HDL-cholesterol (P ¼ 0.0385 in ovulatory
and P ¼ 0.0210 in anovulatory PCOS) and small, dense LDL levels
(P ¼ 0.0468 in ovulatory and P ¼ 0.0335 in anovulatory PCOS) as
well as with triglyceride concentrations in the group of ovulatory
.............................................................................................................................................................................................
Table I Clinical and laboratory characteristics in all subjects
Controls (n 5 27) Ov-PCOS (n 5 15) Anov-PCOS (n5 35) ANOVA *P
Age (years) 30+8 30+6 25+6a,b 0.0053
Body-mass index (kg/m2) 25+4 25+3 28+6 0.0264
Waist (cm) 80+6 85+7 94+14a 0.0044
Total testosterone (nmol/l) 1.0+0.4 2.1+0.8 3.0+1.2 ,0.0001
Insulin (pmol/l) 45+13 65+25a 109+44a,b ,0.0001
HOMA 1.1+0.3 2.0+0.8a 3.3+1.4a,b ,0.0001
Results are shown as mean+ SD.
*Age and BMI adjusted.
aP, 0.05 versus Controls; bP, 0.05 versus Ov-PCOS.
HOMA, homeostasis model assessment.
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PCOS only (P ¼ 0.0433). Further, waist circumference was indepen-
dently associated with levels of small, dense LDL in the group of
anovulatory PCOS (P ¼ 0.489).
Discussion
Cardiovascular diseases represent the major cause of death in both
genders, but women have hormonal protection before menopause
thus delaying the onset of cardiovascular diseases by 10–15 years in
comparison to men (National Cholesterol Education Program,
2002); however, young women may show increased cardiovascular
risk when affected by PCOS (Lobo and Carmina, 2000). The
explanation for such increased risk is still not clear; hyperandrogenism,
as isolated androgen excess, has not been recognized so far as a risk
factor for cardiovascular disease (Legro, 2003) and prospective
studies performed on pre- and post-menopausal women failed to
show a clear association between hyperandrogenism and future cardi-
ovascular events (Cussons et al., 2006). By contrast, other metabolic
conditions, including insulin resistance and dyslipidemia, seems to play
a major role on cardiovascular risk in PCOS (Rizzo et al., 2009). Yet,
to what extent dyslipidemia may contribute to this increased risk is still
largely unknown.
.............................................................................................................................................................................................
Table II Plasma lipids and lipoproteins in all subjects
Controls (n 5 27) Ov-PCOS (n5 15) Anov-PCOS (n5 35) ANOVA *P
Total cholesterol (mmol/l) 4.3+1.2 4.6+1.0 4.9+0.8a 0.0440
Triglycerides (mmol/l) 0.6+0.4 1.0+0.5a 1.0+0.4a 0.0014
HDL-cholesterol (mmol/l) 1.5+0.7 1.4+0.3 1.2+0.3a,b 0.0209
LDL-cholesterol (mmol/l) 2.7+1.6 2.6+1.2 3.5+1.0a,b 0.0282
Lp(a) (mg/dl) 6+6 21+37 40+38a,b 0.0106
Log Lp(a) 0.60+0.39 0.86+0.62 1.39+0.50a,b ,0.0001
apoB (mg/dl) 81+44 84+20 86+25 ns
LDL size (A˚) 290+19 278+12a 276+10a 0.0040
Total small, dense LDL (%) 31+6 37+7a 42+8a,b ,0.0001
Results are shown as mean+ SD.
*Age and BMI adjusted.
aP, 0.05 versus Controls; bP, 0.05 versus Ov-PCOS.
HDL, high-density lipoprotein; LDL, low-density lipoprotein; Lp(a), lipoprotein(a); apoB, apolipoprotein B.
Figure 1 LDL subclasses in all subjects (mean þ SD).
*P, 0.05 versus controls; †P, 0.05 versus Anov-PCOS.
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Lipid alterations are common in women with PCOS (Legro et al.,
2001; Cussons et al., 2006) and we have previously reported in our
Mediterranean PCOS population that triglyceride and LDL-cholesterol
concentrations are usually in the normal range, although signiﬁcantly
increased compared with controls, although HDL-cholesterol levels
are decreased (Essah et al., 2008). Evidence is accumulating that,
beyond plasma lipids, alterations in lipoprotein patterns signiﬁcantly
increase cardiovascular risk (Rizzo and Berneis, 2007; Wierzbicki,
2008). We have previously shown that Mediterranean women with
PCOS display increased concentrations of Lp(a) and small, dense
LDL, with no alterations in apoB levels (Berneis et al., 2007, 2009).
However, this observation is not consistent with ﬁndings by other
authors, particularly in terms of LDL size (Legro et al., 1999), apoB
(Demirel et al., 2007) and Lp(a) (Sahin et al., 2007) concentrations.
This may be due to genetic and environmental factors and may
reﬂect the heterogeneity of PCOS phenotypes.
According to new diagnostic criteria (Rotterdam, 2004; Azziz et al.,
2006) PCOS may indeed represent a wide spectrum of abnormalities,
including women with milder forms of the syndrome who generally
present less severe clinical and hormonal abnormalities (Carmina,
................................................................... ...................................................................
.............................................................................................................................................................................................
Table IV Spearman correlations between lipid parameters and testosterone, insulin and insulin resistance (by HOMA) in
ovulatory and anovulatory PCOS
Ov-PCOS Anov-PCOS
Insulin HOMA Testosterone Insulin HOMA Testosterone
Total cholesterol 0.001 0.030 0.264 20.088 20.066 0.207
Triglycerides 0.343 0.427a 0.056 0.351a 0.392a 0.204
HDL-cholesterol 20.481a 20.465a 20.133 20.381a 20.338a 20.158
LDL-cholesterol 20.062 20.030 0.252 0.163 0.119 0.221
Log Lp(a) 0.084 0.042 20.140 0.168 0.162 20.023
apoB 0.036 0.070 20.103 0.091 0.125 20.047
LDL size 20.302 20.419a 20.134 20.525b 20.492b 20.210
Total small, dense LDL 0.427a 0.461a 0.115 0.548b 0.518b 0.078
HDL, high-density lipoprotein; LDL, low-density lipoprotein; Lp(a), lipoprotein(a); apoB, apolipoprotein B; HOMA, homeostasis model assessment.
aP, 0.05; bP, 0.005.
........................................................................................
Table III Prevalence of plasma lipid and lipoprotein
alterations in ovulatory and anovulatory PCOS
Ov-PCOS
(n5 15)
P 5 Anov-PCOS
(n5 35)
High triglycerides
(.1.7 mmol/l), n (%)
1 (7%) ns 3 (9%)
High LDL-cholesterol
(.4.1 mmol/l), n (%)
1 (7%) ns 8 (23%)
Low HDL-cholesterol
(,1.29 mmol/l), n (%)
5 (33%) 0.0299 24 (69%)
Elevated Lp(a)
(.30 mg/dl), n (%)
3 (20%) 0.0566 19 (54%)
Elevated apoB
(.100 mg/dl), n (%)
1 (7%) ns 11 (31%)
High small, dense LDL
(LDL-III and -IV), n (%)
3 (20%) 0.0302 20 (57%)
HDL, high-density lipoprotein; LDL, low-density lipoprotein; Lp(a), lipoprotein(a);
apoB, apolipoprotein B.
............................................................................... .................................................................................
.............................................................................................................................................................................................
Table V Multivariate analysis (by multiple regression) determining independent predictors of plasma lipids and
lipoproteins in ovulatory and anovulatory PCOS
Ov-PCOS Anov-PCOS
HDL-cholesterol TG Lp(a) apoB Small,
dense LDL
HDL-cholesterol TG Lp(a) apoB Small,
dense LDL
Age ns ns ns ns ns ns ns ns ns ns
BMI ns ns ns ns ns ns ns ns ns ns
Waist
circumference
ns ns ns ns ns ns ns ns ns 0.0489
HOMA 0.0385 ns ns ns 0.0468 0.0210 0.0433 ns ns 0.0335
Testosterone ns ns ns ns ns ns ns ns ns ns
TG: triglycerides; apoB: apolipoprotein B.
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2006; Barber et al., 2007). In particular, patients with the ovulatory
form of PCOS are generally leaner and have lower insulin concen-
trations and higher insulin sensitivity than patients with the classic
anovulatory hyperandrogenic phenotype (Carmina, 2006; Barber
et al., 2007). In the present study we have conﬁrmed that ovulatory
PCOS patients are less obese and display lower testosterone and
insulin concentrations than women with the classic anovulatory
phenotype. It should be noted, however, that there are several
issues concerning the measurement of female testosterone (Rosner
et al., 2007), and it may inﬂuence the reported results.
We also found that women with ovulatory PCOS have lower total-
cholesterol, triglyceride and LDL-cholesterol concentrations and
higher HDL-cholesterol levels as compared with anovulatory PCOS;
further, they showed increased Lp(a) concentrations and reduced
levels of small, dense LDL. The elevation in triglyceride levels may rep-
resent the main contributor for the production of small, dense LDL:
these particles are usually formed by the action of hepatic lipase
from lipoprotein precursors enriched in triglycerides (Rizzo and
Berneis, 2007). Therefore, although the Friedewald’s formula is
appropriate for the calculation of LDL-cholesterol concentrations
when triglycerides are below 4.5 mmol/l, its use in the presence of
abnormal lipoproteins may be problematic. Overall, women with
ovulatory PCOS display a milder form of atherogenic dyslipidemia as
compared with the anovulatory phenotype. Correlation analysis
revealed that such alterations may reﬂect the extent of insulin resist-
ance. Of interest, no signiﬁcant correlations were found between tes-
tosterone levels and plasma lipids and lipoproteins in either PCOS
phenotype, suggesting a limited role of testosterone in modulating
atherogenic dyslipidemia. This is consistent with previous ﬁndings in
PCOS populations (Pirwany et al., 2001).
It should be noted that in the present study we did not match
ovulatory and anovulatory PCOS for age, BMI or waist circumference.
Although the difference in BMI could contribute to differences in
insulin resistance, we preferred to not match these two subgroups
for such parameters in order to include women with their usual and
distinct phenotypes. In fact, ovulatory and anovulatory PCOS generally
exhibit signiﬁcant differences in BMI and waist circumference. Matching
ovulatory with anovulatory PCOS for BMI and waist circumference
would exclude the majority of women with ovulatory PCOS, including
only those with elevated BMI and waist circumference (i.e. mostly
overweight and obese subjects). This may lead to a bias, including
only ovulatory PCOS women with unusual phenotype. Yet, we
adjusted all laboratory data for age and BMI in order to remove the
effects of these potential confounding factors.
We also performed multivariate analyses in order to determine
potential independent predictors of plasma lipids and lipoproteins in
ovulatory and anovulatory PCOS. We found that insulin resistance
was independently associated with HDL-cholesterol and small,
dense LDL levels in both groups of PCOS as well as with triglyceride
concentrations in the group of ovulatory PCOS only. Further, waist
circumference was independently associated with levels of small,
dense LDL in the group of anovulatory PCOS. These ﬁndings
suggest a limited role of obesity, speciﬁcally abdominal obesity, in
determining dyslipidemia in PCOS, although insulin resistance seems
to have a greater role.
At present we do not know whether therapeutic modulation of
such pro-atherogenic lipid alterations reduces cardiovascular risk.
Management of atherogenic dyslipidemia in PCOS is in debate;
weight reduction and increasing physical activity should constitute ﬁrst-
line measures. Lipid-lowering drugs, including statins, nicotinic acid and
ﬁbrates as well as insulin-sensitizing medications or the combination
pioglitazone þ metformin may be an option for patients with severe
dyslipidemia (Rizzo et al., 2008). It remains to be tested in future pro-
spective studies whether hypolipidemic and/or insulin-sensitizing
agents may reduce the cardiovascular risk in women with PCOS by
decreasing atherogenic dyslipidemia.
In conclusion, this is the ﬁrst report focusing on alterations in plasma
lipids and lipoproteins in ovulatory versus anovulatory PCOS pheno-
type. We found milder forms of atherogenic dyslipidemia in ovulatory
than anovulatory PCOS and these alterations were linked to the
degree of insulin resistance. Thus, measurement of atherogenic lipo-
proteins such as Lp(a) and small, dense LDL in women with different
PCOS phenotypes may potentially help to assess cardiovascular risk
and adapt the treatment goals.
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